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Abstract
Background: Dendritic Cell (DC) vaccination is a very promising therapeutic strategy in cancer
patients. The immunizing ability of DC is critically influenced by their migration activity to lymphatic
tissues, where they have the task of priming naïve T-cells. In the present study in vivo DC migration
was investigated within the context of a clinical trial of antitumor vaccination. In particular, we
compared the migration activity of mature Dendritic Cells (mDC) with that of immature Dendritic
Cells (iDC) and also assessed intradermal versus subcutaneous administration.
Methods: DC were labelled with 99mTc-HMPAO or 111In-Oxine, and the presence of labelled DC
in regional lymph nodes was evaluated at pre-set times up to a maximum of 72 h after inoculation.
Determinations were carried out in 8 patients (7 melanoma and 1 renal cell carcinoma).
Results:  It was verified that intradermal administration resulted in about a threefold higher
migration to lymph nodes than subcutaneous administration, while mDC showed, on average, a six-
to eightfold higher migration than iDC. The first DC were detected in lymph nodes 20–60 min after
inoculation and the maximum concentration was reached after 48–72 h.
Conclusions: These data obtained in vivo provide preliminary basic information on DC with
respect to their antitumor immunization activity. Further research is needed to optimize the
therapeutic potential of vaccination with DC.
Background
Dendritic Cell (DC) vaccination is one of the most prom-
ising tools of immunological therapy for cancer. Adminis-
tration of DC, generated and loaded with tumor antigens
ex vivo, can be used to circumvent tumor immunotoler-
ance [1,2]. A large number of immature DC (iDC) can be
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produced by culturing peripheral blood monocytes with
GM-CSF and IL-4 in vitro. These iDC possess functional
characteristics typical of this maturation status, such as
phagocytosis, macropinocytosis, receptor-mediated endo-
cytosis and antigen processing [3,4]. After antigen uptake
and processing, under inflammatory stimuli, iDC
undergo functional changes that result in their maturation
(mDC) [5]. Following the up-regulation of HLA class I
and II and costimulatory molecules (CD80, CD86) and
other specific markers such as CD83, DC-LAMP and
CCR7, mDC migrate to the T-cell zone of lymphoid tissue,
where they have an optimal stimulatory capacity [6,7].
The migration of DC to regional lymph nodes therefore
represents one of the most important requirements for
lymphocyte priming. Migration probably occurs through
lymphatic pathways, but it is not known whether it is
active or passive. Furthermore, factors such as PGE2 may
considerably increase migration, inducing CCR7 expres-
sion on the surface of DC. Penetration may be limited to
the peripheral zones of lymphoid tissue when the DC are
still immature, or may reach the deeper T-cell zones,
where a greater number of naïve T-cells are present, when
DC are mature and activated.
Surface antigen CCR7, present on the cell membrane of
DC, strongly influences migratory capacity through its
interaction with transporter molecules, TREM-2, LTC4,
LTD4, etc. [8-10]. The mDC that reach lymph nodes
prime naïve T-cells for a limited time and then exhaust
their active functions. This can be verified by measuring
IL-12 production, which rapidly decreases, and by deter-
mining the presence of IL-10, previously absent. Special
conditions such as the linkage with lymphocyte ligand
CD40 may prolong the active phase of mDC [11-13].
Recent studies on cancer patients evaluating the efficacy of
in vitro-generated vaccines have shown that mature, but
not immature DC, induce an effective antitumor response
[14-18]. Animal studies have provided direct evidence
that subcutaneously injected DC preferentially migrate to
draining lymph nodes to induce a measurable antitumor
effect [18,19]. Similarly, the use of radiolabelled DC in
humans demonstrates the ability of these cells to migrate
to draining lymph nodes. It has also been observed that
migration efficiency is linked to their maturation status or
administration route (intravenous, subcutaneous, or
intradermal) [20-23].
In the course of a vaccination trial using DC pulsed with
autologous tumor lysate (ATL) in cancer patients, we eval-
uated the in vivo migration ability of DC by labelling them
with 99mTc-HMPAO or 111In-Oxine. In particular, migra-
tory activity was assessed in iDC and mDC in terms of
time required for migration to lymph nodes, duration of
activity, and number of cells that migrated. Migratory
capacity was further evaluated by comparing subcutane-
ous and intradermal administration.
Materials and methods
Patients
The case series consisted of a subset of the 19 patients
enrolled onto a phase I/II vaccination trial for advanced
melanoma and renal cell carcinoma in which the first 9
patients were treated with iDC and the remaining 10
received mDC, both pulsed with autologous tumor lysate
and keyhole limpet hemocyanin (Biosyn, Fellbach, Ger-
many). In the present study 8 patients were analyzed (7
melanoma, 1 renal carcinoma) for a total of 11 treat-
ments. In vivo migration was assessed using a part of the
DC obtained for one of the therapy cycles. Three of the 8
patients were evaluated twice.
Two melanoma patients were treated with iDC (one of
whom twice), while 4 other patients with melanoma and
1 with renal cell carcinoma (treated twice) received mDC.
The remaining melanoma patient was treated with iDC
and subsequently with mDC.
The clinical trial was approved by the Italian Ministry of
Health and by the Ethical Committee of Forlì Health and
Social Services (Azienda USL – Forlì, Italy). All patients
gave written informed consent.
Tumor lysate
Tumor samples surgically removed from the patients were
immediately placed in PBS. Adjacent non malignant tis-
sue was removed by scalpel and tumor cells were dis-
persed to create a single-cell suspension. Cells were lysed
by incubation in sterile distilled water. Lysis was moni-
tored by light microscope. Larger particles were removed
by centrifugation (10 min at 600 g) and the supernatant
was passed through a 0.2-µm filter. Protein contents were
determined and aliquots were stored at -80°C until use.
Treatment
Patients were generally vaccinated intradermally with DC
(4–6 inoculations at the base of the thigh, about 10 cm
from the groin, in the absence of visible disease). From
days 2–6, IL-2 (Chiron, Milan, Italy) was administered
subcutaneously at a dose of 3 million IU/die. This proce-
dure was repeated after two weeks and once a month until
progression occurred.
DC generation
DC were prepared from peripheral blood monocytes
(PBMC) obtained by leukapheresis without previous
mobilization. 5–9 liters of blood were processed in each
collection. PBMC were purified on Ficoll-Paque. An aliq-
uot of PBMC was utilized immediately for DC generationJournal of Translational Medicine 2004, 2:27 http://www.translational-medicine.com/content/2/1/27
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and the rest was frozen in bags for use at a later date (4–5
bags/1 collection).
PBMC were incubated in tissue culture flasks with CellGro
DC Medium (Cell Genix, Freiburg, Germany) at 10 × 106
cells/ml for 2 h. The non-adherent cells were discarded
and the adherent cells were incubated in CellGro DC
Medium containing 1000 IU/ml rhIL-4 (Cell Genix) and
1000 IU/ml rhGM-CSF (Shering Plough, Milan, Italy) for
7 days to generate a DC-enriched cell population. On day
6 DC were pulsed with autologous tumor lysate (100 mg/
ml) and with KLH (50 mg/ml) and incubated overnight.
On day 7, they were defined as iDC. After eliminating the
previous culture medium, pulsed iDC were cultured for a
further 2 days with a cocktail of cytokines (TNFα, IL-1β,
IL-6, Endogen, Pierce Biotechnology, Rockford, USA;
PGE2, Cayman Chemical, Ann Arbor, MI, USA). On day 9
they were defined as mDC. iDC or mDc were removed,
washed and suspended in sterile saline for therapeutic
infusion into the patient.
DC labelling and migration evaluation
Labelling of DC was performed according to the methods
described for leucocyte radiolabelling [24-26]. A part of
both iDC and mDC destined for vaccination (about
9.106) were resuspended in platelet-poor autologous
plasma (CFP1) and incubated for 15 min at room temper-
ature with 99mTc-HMPAO (20 mCi) (Nycomed Amer-
sham plc, Little Chalfont, UK) 111In-Oxine (1 mCi)
(Altana Pharma, Milan, Italy). After two washes to elimi-
nate the unbound isotope, the cells were resuspended in a
total volume of 1.5 ml of CFP1. Radiolabelling of the DC
and of the culture supernatant was evaluated with a
gamma counter, after which DC were inoculated intrader-
mally into the patient near healthy lymph nodes and in
the contralateral zone not used for therapeutic vaccina-
tion (3 inoculations at 10 cm from inguinal or axillary
lymph nodes). The patient then underwent serial acquisi-
tions with gamma-camera positioned at the site of inocu-
lation, with a field of view that included all the lymphatic
regions of interest. The first acquisition was performed
with a dynamic study of 20 min, followed by 10-min
static acquisitions carried out every 30 min for the first 4–
6 h and from 18 to 28 h. Other static determinations were
made at 36, 48 and 72 h. The maximum duration of
observation of DC migratory activity, which depended on
the half-life of the radioisotope used, was 72 h for 111In-
Oxine and 36 h for 99mTc-HMPAO.
The identification of lymph node stations involved in the
migratory activity was initially visual, after which we car-
ried out a semiquantitative evaluation of the percentage of
DC that migrated to lymph nodes from the inoculation
site and an assessment of the speed of DC migration,
expressed by activity/time curves obtained through the
compartmental mathematical model.
Evaluation of labelling stability
DC obtained from the culture of frozen PBMC were
divided into two parts: one was labelled with 99mTc-
HMPAO and the other was labelled with 111In-Oxine. The
labelled cells were then suspended in CellGro DC
Medium, divided into 4–5 culture flasks for each labelling
molecule and incubated for 0 h, 4 h, 21 h, 24 h (99mTc-
HMPAO) and 0 h, 4 h, 21 h, 24 h, 48 h (111In-Oxine). The
DC from one flask were removed and centrifuged. The
supernatant containing the free molecule, and the pellet
containing the labelled cells, were then measured with a
gamma counter.
Phenotype analysis
iDC and mDC phenotypes were determined by single or
two-color fluorescence analysis. 3–5·105 cells were sus-
pended in 100 µl of buffer (PBS, 2% FCS, 1% sodium
azide) and incubated for 30 min at 4°C with 10 µl of
appropriate fluorescein isothiocyanate or phycoerythrin-
labelled monoclonal antibodies (mAbs). The cells were
then washed twice and resuspended in 500 µl of assay
buffer. The fluorescence was analyzed by a FACS Vantage
flow cytometer (Becton Dickinson, Milan, Italy). mAbs
specific for human CD1a, CD14, CD80, CD86, (Becton
Dickinson) CD83 (Immunotech, Marseille, France) and
CCR7 (BD Pharmingen, Milan, Italy) were used.
Cytokine production
At each pre-set time the supernatant was collected and
stored at -80°C until analysis was carried out using com-
mercially available ELISA Kit (Biosource, Nivelles, Bel-
gium) to measure the production of IL-12 + p40
(bioactive heterodimer of IL-12) and IL-10 by DC.
Endocytosis evaluation
Single cell-based measurement of endocytosis was carried
out as described (27). Dendritic cells were incubated for
30 min at 37°C with 0.5 mg/ml FITC-Dextran (40S DX-
FITC Sigma, Milan, Italy). DX-FITC (average MW 42,000)
was centrifuged before use to remove aggregates. As nega-
tive control, cells were incubated with DX-FITC at 4°C.
The cells were washed with cold PBS containing 2% FCS
and 2 nM sodium azide to exclude dead cells and were
then analyzed on a FACS Vantage flow cytometer (Becton
Dickinson) [27].
Results
Patient characteristics
All the patients (6 males, 2 females) had advanced disease
and all but one had undergone previous treatment.
Median age was 49 years (range 46–52 years). Three
patients were HLA-A1, 3 were HLA-A3, 1 was HLA-A2 andJournal of Translational Medicine 2004, 2:27 http://www.translational-medicine.com/content/2/1/27
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1 was HLA-A11 (Table 1). Two melanoma patients were
treated with iDC, while 2 other patients with melanoma
and 1 with renal cell carcinoma received mDC. The
remaining 3 melanoma patients were treated with iDC
and subsequently with mDC (Table 1). The 8 patients
received a total of 73 therapeutic vaccination cycles (20
with DC obtained from fresh PBMC and 53 from frozen
PBMC) and 11 labelled DC evaluations were carried out.
DC characteristics
The characteristics of iDC and mDC used to evaluate
migration activity were similar to those of the DC utilized
by us for therapeutic vaccination and to results published
in the literature. Data on the purity and vitality of DC, the
presence of surface markers and DC functional features
(endocytosis and production of IL-12 and IL-10) are
reported in Table 2.
DC labelling efficiency and stability
The in vitro stability of DC labelled with 99mTc-HMPAO
and  111In-Oxine was evaluated using DC cultured from
frozen PBMC. 99mTc-HMPAO-labelled DC showed a 75%
loss of activity 4–24 h after the beginning of in vitro cul-
ture. 111In-Oxine-labelled DC showed a higher labelling
stability (50%) that lasted for up to 24 h (Fig. 1). This
accounts for the differences in lymph node uptake
percentages observed in our migration studies. More accu-
rate information on the linkage stability of 111In-Oxine-
labelled DC over time would permit the opportune cor-
rection of the uptake percentage and would enable data to
be compared with those obtained using indium.
Administration routes
The migration activity of mDC administered simultane-
ously by intradermal and subcutaneous injection in the
arms of two patients (nos. 7 and 8) was evaluated by com-
paring radioactive uptake in axillary lymph nodes. The
intradermal route showed a threefold higher migration
than that observed for the subcutaneous route (Table 3).
Evaluations were made at intervals from 0 to 44 h after
inoculation. The sites of inoculation showed an exponen-
tial type washout that was virtually identical for both
Table 1: Patient characteristics
Patients Sex/Age Pathology Site of Metastasis Previous 
Treatment
i/mDC HLA
1 M/47 Mel Liver, mediastinal lymph nodes IFN iDC A1A2B8B35Bw6Cw4Cw7
2 M/52 Mel Liver BIOCT iDC A3A28B35B53Cw4
3 M/49 Mel Liver, adrenal glands No treatment iDC + mDC A11A31B14B60Bw6Cw3
4 M/42 Mel Liver, mediastinal and axillary lymph nodes BIOCT iDC+ mDC A1A9B17Bw4Bw6Cw3Cw4
5 F/49 Mel Lung, lymph nodes, skin, peritoneum BIOCT iDC+ mDC A1A9B7B44Bw4Bw6Cw4Cw7
6 M/50 Renal ca. Skin, adrenal glands BIOCT mDC A2A3B7B51Bw4Bw6Cw1Cw7
7 F/52 Mel Lung, liver HdIFN + CT mDC A3A29B44Bw4
8 M/46 Mel Abdominal lymph nodes IFN+BIOCT mDC A3A28B21B35Cw4
IFN, alpha interferon; BIOCT, biochemotherapy; CT, chemotherapy; HdIFN, high-dose adjuvant alpha interferon (ECOG 1684)
Table 2: Biological characteristics of dendritic cells used for vaccination
iDC median % (range) mDC median % (range)
DC surface markers:
CD 1a 20 (4–58) 2 (0–8)
CD 14 3 (0–7) 2 (0–11)
CD 80 3 (1–23) 37 (27–87)
CD 86 30 (10–55) 81 (15–94)
HLA-DR 45 (17–82) 78 (56–88)
CD 83 2 (0–13) 55 (34–73)
CCR7 4 (2–5) 86 (48–92)
Endocytosis % of positive cells 70 (39–91) 15 (1–42)
IL-12 production pg/ml 49 (17–225) > 1350
IL-10 production pg/ml 0 0
% purity * 74 (66–98) 59 (31–100)
% vitality ** 75 (68–79) 82 (66–89)
* viable DC/viable DC + viable lymphocytes ** viable DC + viable lymphocytes/total cellsJournal of Translational Medicine 2004, 2:27 http://www.translational-medicine.com/content/2/1/27
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routes of administration (data not shown). The final
migration percentage ratio (measured after 44 h) was
fairly similar in both patients, but was obviously not sta-
tistically significant (Fig. 2A,2B,3).
iDC/mDC migration
iDC and mDC migration was evaluated in all 8 patients (4
iDC and 7 mDC treatments) (Table 4). The data presented
refer to 4 groups of patients treated with mature or
A sample of mature dendritic cells cultured in vitro for vaccination was divided into two parts, one labelled with 99mTc-HMPAO  and the other with 111In-Oxine Figure 1
A sample of mature dendritic cells cultured in vitro for vaccination was divided into two parts, one labelled with 99mTc-HMPAO 
and the other with 111In-Oxine. The DC were then suspended in DC medium and cultured in vitro for 24 h (99mTc-HMPAO) 
and 48 h (111In-Oxine). At 0, 4, 21, 24, and 48 h, the activity of the supernatant containing the free molecule and of the pellet 
containing labelled cells was measured. After 24 h, a 75% and 50% loss of activity was observed for 99mTc-HMPAO-and 111In-
Oxine-labelled DC, respectively.
Table 3: Different vaccine administration routes: intradermal vs. subcutaneous lymph node uptake
Patients mDC × 106 Administration route Isotope Max uptake (%) *
R.L. (no. 7) 4 Intradermal 99mTc-HMPAO 0.95
G.D. (no. 8) 4 Intradermal 99mTc-HMPAO 1.02
R.L. (no. 7) 4 Subcutaneous 99mTc-HMPAO 0.30
G.D. (no. 8) 4 Subcutaneous 99mTc-HMPAO 0.37
UPTAKE RATIO: intradermal/subcutaneous average: 3 *Maximum uptake = maximum lymph node activity/inoculation site activity at 0 h
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 1 01 21 41 61 82 02 22 42 62 83 03 23 43 63 84 04 24 44 64 85 0
time (hours)
%
 
l
a
b
e
l
l
e
d
 
a
c
t
i
v
i
t
y
99mTc-HMPAO
111In-OxineJournal of Translational Medicine 2004, 2:27 http://www.translational-medicine.com/content/2/1/27
Page 6 of 11
(page number not for citation purposes)
In patients no. 7 (A) and 8 (B), the same number of 99mTc-HMPAO-labelled DC were administered simultaneously: subcutane- ously (sc) in the left axilla and intradermally in the right axilla (id) Figure 2
In patients no. 7 (A) and 8 (B), the same number of 99mTc-HMPAO-labelled DC were administered simultaneously: subcutane-
ously (sc) in the left axilla and intradermally in the right axilla (id). The acquisition times with gamma camera are reported along 
the X-axis and the Y-axis shows the counts per 10 min. In both patients intradermal administration presents a greater concen-
tration of labelled cells in lymph nodes than the subcutaneous route.
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immature cells labelled with 111In-Oxine or 99mTc-
HMPAO. A simple numerical analysis shows that the max-
imum uptake ratio between 99mTc-HMPAO-labelled mDC
and iDC varies from 2 to 35, with an average of 8.4. The
same ratio for 111In-Oxine-labelled cells varies from 4 to
7, with an average of 6. 99mTc-HMPAO labelling is influ-
enced by the very low iDC uptake due to its greater bind-
ing instability and to the short half-life of the
radioisotope, which does not permit the acquisition of
reliable counts beyond 24–36 h.
A lymph node uptake can be observed in all patients
within the first two hours of inoculation, reaching a max-
imum uptake after 12 h in 7 patients (Fig. 4A,4B,5). In the
last 4 experiments in which a more accurate temporal
analysis was performed, the uptake percentage continued
to increase for the entire temporal range studied (24–30 h
with  99mTc-HMPAO and 48–60 h with 111In-Oxine). A
curve fitting analysis also seemed to indicate a progressive
increase in uptake after the first 60 h, but the number of
patients evaluated is too low for any definitive conclu-
sions to be drawn.
Pure 99mTc-HMPAO injection
After injection of 99mTc-HMPAO alone in the same inocu-
lation sites used for the study, no labelled hot spots were
observed. This would seem to suggest that pure tracers
In patient no. 7 the same number of 99mTc-HMPAO-labelled DC were administered simultaneously: subcutaneously (s.c.) in the  left axilla and intradermally (i.d.) in the right axilla Figure 3
In patient no. 7 the same number of 99mTc-HMPAO-labelled DC were administered simultaneously: subcutaneously (s.c.) in the 
left axilla and intradermally (i.d.) in the right axilla. The figure shows acquisition images with gamma camera at 0, 3, 5, and 18 h 
after inoculation. Greater migration capacity after intradermal administration is clearly visible. (IS, inoculation site: LN, lymph 
node).Journal of Translational Medicine 2004, 2:27 http://www.translational-medicine.com/content/2/1/27
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This figure shows the migration activity of mDC (patient no. 5) and iDC (patient no. 2) labelled with 99mTc-HMPAO (A) and of  mDC and iDC (patient no. 3) labelled with 111In-Oxine (B) Figure 4
This figure shows the migration activity of mDC (patient no. 5) and iDC (patient no. 2) labelled with 99mTc-HMPAO (A) and of 
mDC and iDC (patient no. 3) labelled with 111In-Oxine (B). The acquisition times with gamma camera are reported along the 
X-axis and the Y-axis shows the counts per 10 min. mDC migrating to regional lymph node are always higher than iDC. 99mTc-
HMPAO-labelled DC were detected in lymph nodes within 1 h of administration and the maximum concentration was reached 
within 60 min for iDC and between 18 and 20 h after inoculation for mDC.
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move through lymphatic vessels without accumulating
inside lymph nodes.
Discussion
DC-based immunotherapy has undergone a remarkable
transformation in its development from basic research to
clinical application [10,28]. However, many issues
remain to be clarified to improve functionality and thera-
peutic effects and to insure a powerful and wide-ranging
antitumor response by T-cells. Two stages of fundamental
importance in the therapeutic use of DC are the optimiza-
tion of the maturation stimulus and the induction of an
effective migration to regional lymph nodes to guarantee
powerful and long-lasting priming of naïve T-cells [5,29].
Migration activity is therefore one of the functional char-
acteristics of DC that warrants further investigation in an
attempt to increase their potential [30].
Recent published data have shown that the choice of mat-
uration stimulus may be crucial for therapeutic success. In
particular, it has been seen that PGE2 is essential for acti-
vating DC chemotaxis through the expression of CCR7 on
the cell surface [31,32]. This receptor permits migration
through a concentration gradient of its ligands CCL19 and
CCL21 inside lymphoid organs. The use of PGE2 may
therefore prove to be important for increasing migration
activity and DC efficacy. However, it has also been
observed that PGE2 inhibits IL-12 production, resulting in
a weaker in vivo activation of T-cells [33,34]. These contra-
dictory research data obviously require validation by in
vivo experimentation.
In the present study we aimed to clarify some issues con-
cerning DC migration activity in a clinical vaccination
trial utilizing radiolabelled (99mTc-HMPAO and 111In-
Oxine) iDC and mDC [20,35]. Technetium has a high
The figure shows static acquisition images with gamma camera 2, 24, and 48 h, and 2, 24, 48 and 72 h after inoculation with  111In-Oxine-labelled iDC and mDC, respectively, for patient no. 3 Figure 5
The figure shows static acquisition images with gamma camera 2, 24, and 48 h, and 2, 24, 48 and 72 h after inoculation with 
111In-Oxine-labelled iDC and mDC, respectively, for patient no. 3. Greater migration activity of mDC is clearly visible. (IS, inoc-
ulation site: LN, lymph node).
Table 4: Comparison between iDC and mDC lymph node uptake
Patients DC i/m × 106 Isotope Max uptake 
(%) *
G.C. (no. 1) i 6 99mTc-HMPAO 0.22
G.C. (no. 1) i 6.9 99mTc-HMPAO 0.05
G.L. (no. 2) i 9 99mTc-HMPAO 0.05
P.A.M. (no. 3) i 6 111In-Oxine 0.42
T.N. (no. 5) m 5.6 99mTc-HMPAO 1.75
P.I.M. (no. 4) m 12 99mTc-HMPAO 0.53
PA.M. (no. 3) m 7 111In-Oxine 3.14
S.G. (no. 6) m 6.4 99mTc-HMPAO 0.39
S.G. (no. 6) m 6.7 111In-Oxine 1.88
R.L. (no. 7) m 4 99mTc-HMPAO 0.95
G.D. (no. 8) m 4 99mTc-HMPAO 1.02
UPTAKE RATIO: mDC/iDC 111In-Oxine average: 6 (range 4–7) 
99m Tc-HMPAO average: 8.4 (range 2–35) *Maximum uptake = 
maximum lymph node activity/ inoculation site activity at 0 hJournal of Translational Medicine 2004, 2:27 http://www.translational-medicine.com/content/2/1/27
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labelling intensity and a short half-life, while indium,
despite having a lower intensity, has a longer half-life,
which enabled us to monitor the migration activity of
labelled DC for up to 72 h.
The first step was to evaluate whether radioactive tracer
would be scintigraphically visualized in lymph nodes. For
this purpose technetium alone was injected intradermally
and its progression followed. At the same time labelled
DC were administered in the contralateral zone. It was
seen that the tracer was not entrapped in lymph node sta-
tions and this confirmed that the radioactive molecule
detected in contralateral regional lymph nodes was
undoubtedly the expression of labelled DC that had
migrated to that site.
One of the simplest analyses carried out was the evalua-
tion of mDC migration activity using two different routes
of administration: subcutaneous and intradermal. We
chose two patients at random and compared migration
activity simultaneously in both arms (right intradermal
and left subcutaneous); it was observed that intradermal
administration had a threefold higher migration to lymph
nodes than the subcutaneous route. Although it remains
to clarify the extent to which this migratory capacity is
active or passive, it is clear that DC must be administered
intradermally to obtain a higher migration.
A crucial phase of the study was the comparison between
the migratory activity of iDC (used in the first part of the
clinical trial) and that of mDC (used in the second half of
our ongoing study). The result was once again unequivo-
cal, showing a greater progressive concentration of mDC
that was, on average, six-eightfold higher than that of iDC,
in accordance with data reported by other authors [20,23]
and in contrast to results published by Blocklet [17], who
probably used iDC. The phenotype obtained in our study
bears witness to the fact that mDC exhibit a much higher
CCR7 surface expression than iDC (86% vs. 4%) (Table
2). Furthermore, mDC have an extremely high IL-12 pro-
duction, which confirms a marked stimulatory activity.
Notwithstanding the results obtained from the present
study, many issues remain to be clarified. It has yet to be
determined whether the increased activity detected in
lymph nodes corresponds to an effectively greater migra-
tory capacity or whether it is the result of a more effective
adhesion capacity between surface molecules. Both
hypotheses could even prove to be correct. We also do not
know how long DC remain in lymph nodes. The increase
in activity in lymph nodes is high in the first few determi-
nations but tends to diminish or stabilize after around 36
h. It remains to be seen whether this presumed stabiliza-
tion is the result of a sort of saturation or whether it can
be attributed to the attainment of a dynamic equilibrium.
The former hypothesis would indicate the need for an
optimization of the number of DC to administer, as only
a limited number would be functionally active. The latter
would highlight the importance of the timing of adminis-
tration and perhaps also the degree of DC maturation. To
further investigate this, we plan to administer 111In-
Oxine-and 99mTc-HMPAO-labelled DC in succession and
in the same site, to follow their migratory course.
Finally, we aim to assess the migratory capacity of in vitro
transiently stimulated DC (semimature DC). The thera-
peutic use of this type of DC, which have already begun
the process of maturation and may be capable of reaching
lymph nodes before their functional exhaustion, could
increase the duration of their activation and stimulation.
If these semimature DC prove to be equipped with a good
migratory capacity, further improvement in the therapeu-
tic use of DC may be possible.
Conclusions
The migration activity of DC to regional lymph nodes is
one of the many critical factors that influence the thera-
peutic result of antitumor vaccination. In the present
study we used radioisotope-labelled DC and
demonstrated that a better migration activity is obtained
using intradermal than subcutaneous administration and
that mDC show, on average, a six-to eightfold higher
migration than iDC. Numerous other issues on DC func-
tionality have yet to be clarified before antitumor thera-
peutic efficacy can be improved. The next important step
will be to closely monitor the quantity and quality of
responses observed in T-cells, and it is hoped that a con-
sensus will be reached on standardized criteria for the def-
inition and validation of clinical results obtained.
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